Eli Lilly stock inches higher as the company joins the coveted trillion-dollar club. Citi analysts believe LLY shares will ...

Donald Trump’s family has been pursuing wealth, fame and power in their name for decades, and now that he is a lame-duck ...

Several of the environmental advocates and vaccine skeptics who helped propel Kennedy into politics have become impatient ...

The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...

In summary, under the Trump plan, the U.S. health system continues to fail Americans — by not viewing obesity as a disease, ...

FDA decision-making may be reduced to a sequence of ‘make-a-deals’ with Trump, his FDA, or even political allies,” experts ...

Orforglipron is Lilly’s oral GLP-1 in phase 3 development as a treatment for diabetes and obesity. The FDA is expected to approve the drug in March 2026. Lilly’s November news release states that the ...

Eli Lilly on Friday became the first health care company to top $1 trillion in market capitalization, joining a club of ...

Piper Sandler lowered the firm’s price target on PepsiCo (PEP) to $161 from $162 and keeps an Overweight rating on the shares. The firm says it is ...

Healthcare stocks have outperformed the broader market by nearly 10 percentage points this month as AI bubble concerns have weighed on tech stocks.

The pharmaceutical giant Novo Nordisk, once a high-flying market darling, is implementing a dramatic strategic pivot. Facing intense competitive pressure fro ...